Ticolubant

Drug Profile

Ticolubant

Alternative Names: SB 209247

Latest Information Update: 29 Sep 1998

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Anti-inflammatories; Antipruritics; Antipsoriatics
  • Mechanism of Action Leukotriene B4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Psoriasis

Most Recent Events

  • 29 Sep 1998 Discontinued-Preclinical for Psoriasis in USA (Unknown route)
  • 25 Aug 1997 Preclinical development for Psoriasis in USA (Unknown route)
  • 12 May 1997 SB 209247 is now called ticolubant
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top